These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Design and synthesis of histidine analogues of folic acid and methotrexate as potential folylpolyglutamate synthetase inhibitors. Mao Z; Pan J; Kalman TI J Med Chem; 1996 Oct; 39(21):4340-4. PubMed ID: 8863812 [TBL] [Abstract][Full Text] [Related]
24. Nonpolyglutamatable antifolates as inhibitors of thymidylate synthase (TS) and potential antitumour agents. Bavetsias V; Jackman AL Curr Med Chem; 1998 Aug; 5(4):265-88. PubMed ID: 9668195 [TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. Zhao R; Titus S; Gao F; Moran RG; Goldman ID J Biol Chem; 2000 Aug; 275(34):26599-606. PubMed ID: 10856298 [TBL] [Abstract][Full Text] [Related]
26. Regulation of folate and one-carbon metabolism in mammalian cells. I. Folate metabolism in Chinese hamster ovary cells expressing Escherichia coli or human folylpoly-gamma-glutamate synthetase activity. Osborne CB; Lowe KE; Shane B J Biol Chem; 1993 Oct; 268(29):21657-64. PubMed ID: 8408018 [TBL] [Abstract][Full Text] [Related]
27. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558 [TBL] [Abstract][Full Text] [Related]
28. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099 [TBL] [Abstract][Full Text] [Related]
29. Regulation of folate and one-carbon metabolism in mammalian cells. III. Role of mitochondrial folylpoly-gamma-glutamate synthetase. Lin BF; Huang RF; Shane B J Biol Chem; 1993 Oct; 268(29):21674-9. PubMed ID: 8408020 [TBL] [Abstract][Full Text] [Related]
30. Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase. Tomsho JW; Moran RG; Coward JK Biochemistry; 2008 Aug; 47(34):9040-50. PubMed ID: 18672898 [TBL] [Abstract][Full Text] [Related]
31. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626 [TBL] [Abstract][Full Text] [Related]
32. Update on antifolate drugs targets. Costi MP; Ferrari S Curr Drug Targets; 2001 Jun; 2(2):135-66. PubMed ID: 11469716 [TBL] [Abstract][Full Text] [Related]
34. Mechanism-based inhibition of human folylpolyglutamate synthetase: design, synthesis, and biochemical characterization of a phosphapeptide mimic of the tetrahedral intermediate. Tsukamoto T; Haile WH; McGuire JJ; Coward JK Arch Biochem Biophys; 1998 Jul; 355(1):109-18. PubMed ID: 9647673 [TBL] [Abstract][Full Text] [Related]
35. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier. Zhao R; Gao F; Babani S; Goldman ID Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817 [TBL] [Abstract][Full Text] [Related]
36. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma. Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276 [TBL] [Abstract][Full Text] [Related]
37. A strategy for the design of membrane-permeable folypoly-gamma-glutamate synthetase inhibitors: "bay-region"-substituted 2-desamino-2-methyl-5,8-dideazafolate analogs. Sanghani PC; Jackman A; Evans VR; Thornton T; Hughes L; Calvert AH; Moran RG Mol Pharmacol; 1994 Feb; 45(2):341-51. PubMed ID: 8114682 [TBL] [Abstract][Full Text] [Related]
38. Folate and antifolate pharmacology. Kamen B Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of human liver folylpolyglutamate synthetase by non-gamma-glutamylatable antifolate analogs. Clarke L; Rosowsky A; Waxman DJ Mol Pharmacol; 1987 Jan; 31(1):122-7. PubMed ID: 3807889 [TBL] [Abstract][Full Text] [Related]
40. Mammalian folylpoly-gamma-glutamate synthetase. 3. Specificity for folate analogues. George S; Cichowicz DJ; Shane B Biochemistry; 1987 Jan; 26(2):522-9. PubMed ID: 3828322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]